Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Jan 17 2024

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has issued a press release announcing that it received final approvals from the USFDA for Pimavanserin Capsules and Tablets. These products are indicated for treating hallucinations and delusions associated with Parkinson disease psychosis. The manufacturing will take place at the company's facility in Ahmedabad SEZ, India.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated January 17, 2024, titled "Zydus receives Final Approvals from the USFDA for Pimavanserin Capsules, 34 mg and Pimavanserin Tablets,10 mg".

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases